The clinical epidemiology of human T-lymphotropic virus type II (HTLV- II)

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 13, Issue SUPPL. 1, 1996, Pages

  Murphy, Edward L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUT PASTEUR   (France)

Author keywords

HTLV II infections; Indians, North American; Substance abuse, intravenous

Indexed keywords

AMERICAN INDIAN; BLOOD DONOR; BREAST FEEDING; CONFERENCE PAPER; DRUG DEPENDENCE; HIGH RISK POPULATION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; INFECTION RISK; PRIORITY JOURNAL; RISK FACTOR; SEXUAL TRANSMISSION; VIRUS TRANSMISSION;

BACTERIA (MICROORGANISMS); HTLV; HTLV II; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2;

EID: 0029744214     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199600001-00032     Document Type: Conference Paper

References (21)

1. Hall WW, Kubo T, Ijichi S, Takahashi H, Zhu SW. Human T-cell leukemia/lymphoma virus, type II (HTLV-II): emergence of an important newly recognized pathogen. Semin Virol 1994;5:165-78.
2. Maloney EM, Biggar RJ, Neel JV, et al. Endemic human T-cell lymphotropic virus type II infection among isolated Brazilian Amerindians. J Infect Dis 1992;166:100-7.
3. Hjelle B, Khabbaz RF, Conway GA, North G, Green D, Kaplan JE. Prevalence of human T-cell lymphotropic virus type II in American Indian populations of the southwestern United States. Am J Trop Med Hyg 1994;51:11-5.
4. Goubau P, Liu HF, deLarge GG, V Andamme A-M Desmyter J. HTLV-II seroprevalence in pygmies across Africa since 1970. AIDS Res Hum Retroviruses 1993;9:709-13.
5. Delaporte E, Louwagie J, Peeters M, et al. Evidence for HTLV-II infection in Central Africa. AIDS 1991;5:771-2.
6. Gessain A, Mauclere P, Froment A, et al. Isolation and molecular characterization of a human T lymphotropic virus type II, subtype B, from a healthy pygmy in a remote area of Cameroon: an ancient origin for HTLV-II in Africa. Proc Natl Acad Sci USA 1995;92:4041-5.
7. Khabbaz RF, Onorato IM, Cannon RO, et al. Seroprevalence of HTLV-I and HTLV-II among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med 1992;326:375-80.
8. Feigal E, Murphy EL, Vranizan K, et al. HTLV-I/II in intravenous drug users in San Francisco: Risk factors associated with seropositivity. J Infect Dis 1991;164(1):36-42.
9. Robert-Guroff M, Weiss SH, Giron JA et al. Prevalence of antibodies to HTLV-I and HTLV-II in intravenous drug abusers from an AIDS endemic region. JAMA 1986;255: 3133-7.
10. Eble BE, Busch MP, Guiltinan A, Khayam-Bashi H, Vyas GN, Murphy EL. Determination of human T-lymphotropic virus type by PCR and correlation with risk factors in northern California blood donors. J Infect Dis 1993;167:954-7.
11. Kaplan JE, Khabbaz RF, Murphy EL et al. Male-to-female transmission of human T-lymphotropic virus types I and II: association with viral load. J Acquir Immune Defic Syndr Human Retroviral 1996;12:193-201.
12. Lal RB, Gongora-Biachi RA, Pardi D, Switzer WM, Goldman I, Lal AA. Evidence for mother to child transmission of human T-lymphotropic virus type II. J Infect Dis 1993;168: 586-91.
13. Reeves WC, Cutler JR, Gracia F, et al. Human T-cell lymphotropic virus infection in Guaymi Indians from Panama. Am J Trop Med Hyg 1990;43:410-8.
14. Kaplan JE, Abrams S, Shaffer N. Low risk of mother to child transmission of human T-lymphotropic virus, type II (HTLV-II) in non-breast fed infants. J Infect Dis 1992;166: 892-5.
15. Jacobson S, Lehky T, Nishimura M, Robinson S, McFarlin DE, Dhib-Jalbut S. Isolation of HTLV-II from a patient with chronic, progressive neurological disease clinically indistinguishable from HTLV-I-associated myelopathy/tropical spastic paraparesis. Ann Neurol 1993;33:392-6.
16. Harrington WJ Jr, Sheremata WA, Hjelle B, et al. Spastic ataxia associated with HTLV-II infection. Ann Neurol 1993; 33:411-4.
17. Murphy EL, Fridey J, Smith JW, et al. HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II infected blood donors. AIDS Res and Hum Retrov 1994;10:473.
18. Hjelle B, Appenzeller O, Mills R, et al. Chronic neurodegenerative disease associated with HTLV-II infection. Lancet 1992;339:645-6.
19. Sheremata WA, Harrington WJ, Bradshaw PA, et al. Association of "(tropical) ataxic neuropathy" with HTLV-II. Virus Res 1993;29:71-7.
20. Bhagavati S, Ehrlich G, Kula RW, et al. Detection of human T-cell lymphoma/leukemia virus type I DNA and antigen in spinal fluid and blood of patients with chronic progressive myelopathy. N Engl J Med 1988;318:1141-7.
21. Modahl LE, Young KC, Varney KF, Khayam-Bashi H, Murphy EL. Injection drug users seropositive for human T-lymphotropic virus type II (HTLV-II) are at increased risk for pneumonia, abscess and lymphadenopathy. J Acq Immune Defic Synd and Hum Retrov 1995;10:260.